AZTA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Azenta Inc. (AZTA) is not a strong buy for a beginner, long-term investor at this time. While the company has made strategic acquisitions to enhance its market position and shows potential for future growth, its current financial performance, technical indicators, and sentiment do not support an immediate investment. The stock's recent bearish trend, declining gross margins, and lack of significant positive trading signals suggest holding off for now.
The technical indicators for AZTA show a bearish trend. The MACD is below 0 and negatively contracting, the RSI is neutral at 21.227, and the moving averages indicate a bearish alignment (SMA_200 > SMA_20 > SMA_5). Key support is at 24.471, which is close to the current price of 24.8, suggesting limited downside protection. Resistance levels are at 26.906 and above, indicating the stock may struggle to break higher in the short term.
Acquisition of UK Biocentre to enhance market position in the UK life sciences sector and establish a European operational hub.
Expected positive impact on revenue growth and EBITDA margin in 2027 and
Analysts like Evercore ISI maintain an Outperform rating, citing long-term growth potential.
Declining gross margins (-8.18% YoY) and negative EPS (-0.
despite slight revenue growth.
Recent earnings miss and lower gross margins leading to a 20% stock drop post-earnings.
Neutral trading sentiment from hedge funds and insiders, with no significant activity.
No recent congress trading data or influential figure activity.
In Q1 2026, revenue increased by 0.82% YoY to $148.64M, net income improved by 40.39% YoY but remains negative at -$15.43M, and EPS improved by 41.67% YoY to -0.34. However, gross margin dropped by 8.18% YoY to 42.86%, indicating operational challenges.
Analyst sentiment is mixed. Evercore ISI maintains an Outperform rating with a price target of $45, citing the company's fiscal year and long-range plan. TD Cowen lowered its price target to $30 from $39, expressing concerns over lower gross margins and an earnings miss. Analysts emphasize the importance of North America recovery and multi-year growth frameworks for future positioning.
